Date for Immunicum’s interim report for the period July 2013 – March 2014 changed
April 15, 2014 04:33 ET
|
Immunicum AB
Göteborg, Sweden, 2014-04-15 10:33 CEST (GLOBE NEWSWIRE) --
Immunicum AB (publ) (”Immunicum”) has decided to change the date of publication of its interim report for the period 1 July 2013 – 31...
Immunicum has completed a private placement and resolved on a fully underwritten rights issue
April 02, 2014 02:50 ET
|
Immunicum AB
Göteborg, Sweden, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) --
Not for distribution, directly or indirectly, in or into the United States, Australia, Canada, Singapore, Switzerland, South Africa,...
Immunicum har genomfört en riktad nyemission och beslutat om en fullt garanterad företrädesemission
April 02, 2014 02:50 ET
|
Immunicum AB
Göteborg, 2014-04-02 08:50 CEST (GLOBE NEWSWIRE) --
Ej för distribution, direkt eller indirekt, inom eller till USA, Australien, Kanada, Singapore, Schweiz, Sydafrika, Japan, Hongkong, eller Nya...
Immunicum slutrapporterar positiva fas I/II säkerhetsdata samt lovande överlevnadsdata vid behandling av metastaserande njurcancer
March 31, 2014 02:56 ET
|
Immunicum AB
Göteborg, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) --
Immunicum® AB (publ) har idag lämnat in en slutrapport till Läkemedelsverket avseende sin kliniska fas I/II-studie på 12 patienter med...
Immunicum submits the final report for its phase I/II trial in metastatic renal cell carcinoma showing positive safety data and promising survival data
March 31, 2014 02:56 ET
|
Immunicum AB
Göteborg, Sweden, 2014-03-31 08:56 CEST (GLOBE NEWSWIRE) --
Immunicum® AB (publ) today submitted the final report to the Swedish Medical Products Agency regarding its clinical phase I/II study in 12...
Immunicum meddelar att ett abstract med resultat från en njurcancerstudie har godkänts för presentation på det årliga ASCO-mötet i Chicago
March 27, 2014 05:25 ET
|
Immunicum AB
Göteborg, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) --
Immunicum meddelar att ett abstract har godkänts för presentation vid American Society of Clinical Oncologys, ASCOs, årliga konvent som hålls i...
Immunicum’s abstract with data from a kidney cancer study has been approved for presentation at the 2014 ASCO Annual Meeting in Chicago
March 27, 2014 05:25 ET
|
Immunicum AB
Göteborg, Sweden, 2014-03-27 10:25 CET (GLOBE NEWSWIRE) --
Immunicum today announced that an abstract has been approved to for presentation at the American Society of Clinical Oncology’s’s, ASCO,...
Immunicum reports promising preclinical results for its CD70 technology in adoptive immunotherapy
March 06, 2014 02:40 ET
|
Immunicum AB
Gothenburg, Sweden, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) --
Promising data for Immunicum’s CD70-technology for adoptive immunotherapy are today being published in a scientific journal. The results...
Immunicum rapporterar lovande prekliniska resultat för sin CD70-teknologi inom adoptiv immunterapi
March 06, 2014 02:40 ET
|
Immunicum AB
Göteborg, 2014-03-06 08:40 CET (GLOBE NEWSWIRE) --
Idag publiceras lovande data för Immunicums CD70-teknologi för adoptiv immunterapi. Resultaten indikerar en robust metod att expandera...
Immunicum: Interim Report July - December 2013
February 18, 2014 02:59 ET
|
Immunicum AB
Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) --
Second half of 2013 compared with the same period in 2012
Profit/Loss
The net loss for the period July 1 - December 31, 2013...